Clinical trial · Interventional
Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
Clinical Trial of Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas
NCT01393093CI-TRIAL-00028076TACE-KMGunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effects of Transcatheter Arterial Chemoembolization (TACE) with KMG microsphere in treating advance-stage Hepatocellular Carinoma(HCC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Hepatocellular | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Therapeutic Chemoembolization | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- TACE -oil
- description
- embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
- interventionNames
- Procedure: Therapeutic Chemoembolization
- type
- EXPERIMENTAL
- label
- TACE-KMG ( routine dose Chemo)
- description
- embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
- interventionNames
- Procedure: Therapeutic Chemoembolization
- type
- EXPERIMENTAL
- label
- TACE-KMG( low dose Chemo )
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Hepatocellular Carinomas with diagnosis of pathology or cytology or consistent with China 2001 guideline of Clinical Diagnosis Hepatocellular Carinomas 2. clinical stage（The Barcelona Liver Clinic staging system,BCLC B and C)，or can not receive surgical intervention 3. liver function:Child-Pugh A、B 4. PST 0-1（Eastern Cooperative Oncology Group Performance Score ,ECOG） 5. Lifespan≥6 months 6. First time to receive treatment 7. Can accept the follow up 8. informed consent was gotten 9. the number of lesion ≤ 5 Exclusion Criteria: 1. pregnant or lactation woman 2. emotional disturbance 3. serious heart ,lung disfunction or serious diabetes mellitus 4. serious reactiveness infections;（exp:type B or C hepatitis） 5. liver function :Child-Pugh Score C 6. thrombocyte\<6×109/L 7. diffuse HCC 8. widespread metastasis 9. serious atherosclerosis 10. acquired immunodeficiency syndrome;AIDS 11. thrombosis or thrombosis event in 6 months 12. renal inadequacy who need hemodialysis or peritoneal dialysis 13. with other tumors except basal cell carcinoma and carcinoma in situ of cervix 14. serious alimentary tract hemorrhage in 4 weeks
References
Publications (0)
Data not yet available
No reference posted for this study.